Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance

Journal of Clinical Investigation

Volumn 126, Issue 11, 2016, Pages 4361-4371

  Petersen, Max C ^a   Madiraju, Anila K ^a   Gassaway, Brandon M ^a,b   Marcel, Michael ^a   Nasiri, Ali R ^a   Butrico, Gina ^a   Marcucci, Melissa J ^a   Zhang, Dongyan ^a   Abulizi, Abudukadier ^a   Zhang, Xian Man ^a   Philbrick, William ^a   Hubbard, Stevan R ^c   Jurczak, Michael J ^d   Samuel, Varman T ^a,e   Rinehart, Jesse ^a,b   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLUCOSE; GLYCOGEN; INSULIN RECEPTOR; INSULIN RECEPTOR KINASE; LIPID; PROTEIN KINASE C EPSILON; THREONINE; FAT INTAKE; PRKCE PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CLAMP; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GLUCONEOGENESIS; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; HYPERINSULINEMIA; IN VITRO STUDY; INSULIN RESISTANCE; LIPID DIET; MASS SPECTROMETRY; MOUSE; MUTATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; AMINO ACID SUBSTITUTION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; FAT INTAKE; GENETICS; LIVER; METABOLISM; MISSENSE MUTATION; MUTANT MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PHARMACOLOGY; PHOSPHORYLATION;

AMINO ACID SUBSTITUTION; ANIMALS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; GLYCOGEN; INSULIN RESISTANCE; LIVER; MICE; MICE, MUTANT STRAINS; MUTATION, MISSENSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHORYLATION; PROTEIN KINASE C-EPSILON; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84994613956     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86013     Document Type: Article

References (58)

1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-161
2. Silverman JF, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990;85(10):1349-1355
3. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134(5):1369-1375
4. Marchesini G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450-455
5. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84-91
6. Farese RV, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 2012;15(5):570-573
7. Sun Z, et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med. 2012;18(6):934-942
8. Minehira K, et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res. 2008;49(9):2038-2044
9. Brown JM, et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J Lipid Res. 2010;51(11):3306-3315
10. Monetti M, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007;6(1):69-78
11. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000
12. Samuel VT, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007;117(3):739-745
13. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-871
14. Kumashiro N, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011;108(39):16381-16385
15. Samuel VT, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345-32353
16. Raddatz K, et al. Time-dependent effects of Prkce deletion on glucose homeostasis and hepatic lipid metabolism on dietary lipid oversupply in mice. Diabetologia. 2011;54(6):1447-1456
17. Hubbard SR. The insulin receptor: both a prototypical and atypical receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 2013;5(3):a008946
18. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 1994;372(6508):746-754
19. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997;16(18):5572-5581
20. Turner N, et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia. 2013;56(7):1638-1648
21. Perry RJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745-758
22. Rebrin K, Steil GM, Mittelman SD, Bergman RN. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest. 1996;98(3):741-749
23. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest. 1998;101(6):1203-1209
24. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008;414(1):1-18
25. Cantley JL, et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc Natl Acad Sci U S A. 2013;110(5):1869-1874
26. Chaurasia B, Summers SA. Ceramides-lipotoxic inducers of metabolic disorders. Trends Endocrinol Metab. 2015;26(10):538-550
27. Ozcan U, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457-461
28. Caro JF, et al. Studies on the mechanism of insulin resistance in the liver from humans with noninsulindependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Invest. 1986;78(1):249-258
29. Watarai T, Kobayashi M, Takata Y, Sasaoka T, Iwasaki M, Shigeta Y. Alteration of insulin-receptor kinase activity by high-fat feeding. Diabetes. 1988;37(10):1397-1404
30. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473-481
31. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867
32. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-246
33. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81-87
34. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274
35. Marin O, Meggio F, Perich JW, Pinna LA. Phosphotyrosine specifies the phosphorylation by protein kinase CK2 of a peptide reproducing the activation loop of the insulin receptor protein tyrosine kinase. Int J Biochem Cell Biol. 1996;28(9):999-1005
36. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem. 1997;272(2):952-960
37. Duarte ML, et al. Protein folding creates structure-based, noncontiguous consensus phosphorylation motifs recognized by kinases. Sci Signal. 2014;7(350):ra105
38. Johnson LN. Substrates of mitotic kinases. Sci Signal. 2011;4(179):pe31
39. Vatner DF, et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci U S A. 2015;112(4):1143-1148
40. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656-665
41. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861-867
42. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211-218
43. Pluck A, Klasen C. Generation of chimeras by microinjection. Methods Mol Biol. 2009;561:199-217
44. Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. Methods Mol Biol. 2009;560:221-238
45. Ayala JE, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3(9-10):525-534
46. Passonneau JV, Lauderdale VR. A comparison of three methods of glycogen measurement in tissues. Anal Biochem. 1974;60(2):405-412
47. Cline GW, Shulman GI. Mass and positional isotopomer analysis of glucose metabolism in periportal and pericentral hepatocytes. J Biol Chem. 1995;270(47):28062-28067
48. Shulman GI, Landau BR. Pathways of glycogen repletion. Physiol Rev. 1992;72(4):1019-1035
49. Youngren JF, Goldfine ID, Pratley RE. Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians. Am J Physiol. 1997;273(2 Pt 1):E276-E283
50. Sawyer N, Gassaway BM, Haimovich AD, Isaacs FJ, Rinehart J, Regan L. Designed phosphoprotein recognition in Escherichia coli. ACS Chem Biol. 2014;9(11):2502-2507
51. Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem. 2003;75(3):663-670
52. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367-1372
53. MacLean B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966-968
54. Ramos RR, Swanson AJ, Bass J. Calreticulin and Hsp90 stabilize the human insulin receptor and promote its mobility in the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2007;104(25):10470-10475
55. Schmitz-Peiffer C, et al. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the highfat-fed rat. Diabetes. 1997;46(2):169-178
56. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917
57. Yu C, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277(52):50230-50236
58. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45